Jianfa Wu1,2,3, Huang Chen3, Sihong Wang1,2, Lei Peng1,2, Xiaoying Hu1,2, Zhou Liu1,2,*
Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.070542
- 30 December 2025
Abstract Objectives: Ribosomal protein S6 kinase A2 (RPS6KA2) has been identified as a potential prognostic biomarker in several cancers, including breast cancer, glioblastoma, and prostate cancer. However, its functional significance in ovarian cancer is not well characterized. This study was designed to explore the therapeutic relevance of modulating RPS6KA2 in the context of ovarian cancer, particularly in relation to cisplatin resistance. Methods: The expression levels of RPS6KA2 and key regulators involved in autophagy and ferroptosis were assessed using quantitative reverse transcription-PCR, immunofluorescence staining, immunohistochemistry, and western blotting. Prognostic associations were conducted using the Kaplan-Meier Plotter database.… More >